Neostigmine methylsulfate - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for neostigmine methylsulfate and what is the scope of freedom to operate?
Neostigmine methylsulfate
is the generic ingredient in three branded drugs marketed by Exela Pharma, Adaptis, Am Regent, Amneal, Amphastar Pharms Inc, Amring Pharms, Be Pharms, Caplin, Dr Reddys, Endo Operations, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Meitheal, Sagent Pharms Inc, Umedica, and Avet Lifesciences, and is included in twenty NDAs. Additional information is available in the individual branded drug profile pages.There are nine drug master file entries for neostigmine methylsulfate. Twenty-five suppliers are listed for this compound.
Summary for neostigmine methylsulfate
US Patents: | 0 |
Tradenames: | 3 |
Applicants: | 18 |
NDAs: | 20 |
Drug Master File Entries: | 9 |
Finished Product Suppliers / Packagers: | 25 |
Raw Ingredient (Bulk) Api Vendors: | 104 |
Clinical Trials: | 9 |
Patent Applications: | 2,155 |
Drug Prices: | Drug price trends for neostigmine methylsulfate |
What excipients (inactive ingredients) are in neostigmine methylsulfate? | neostigmine methylsulfate excipients list |
DailyMed Link: | neostigmine methylsulfate at DailyMed |
Recent Clinical Trials for neostigmine methylsulfate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Seoul National University Hospital | N/A |
Alexandria University | Phase 4 |
Kasr El Aini Hospital | Phase 4 |
Pharmacology for neostigmine methylsulfate
Drug Class | Cholinesterase Inhibitor |
Mechanism of Action | Cholinesterase Inhibitors |
Medical Subject Heading (MeSH) Categories for neostigmine methylsulfate
Anatomical Therapeutic Chemical (ATC) Classes for neostigmine methylsulfate
US Patents and Regulatory Information for neostigmine methylsulfate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Amphastar Pharms Inc | NEOSTIGMINE METHYLSULFATE | neostigmine methylsulfate | SOLUTION;INTRAVENOUS | 209933-001 | Sep 25, 2017 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Amneal | NEOSTIGMINE METHYLSULFATE | neostigmine methylsulfate | SOLUTION;INTRAVENOUS | 210051-002 | Jun 15, 2018 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Am Regent | NEOSTIGMINE METHYLSULFATE | neostigmine methylsulfate | SOLUTION;INTRAVENOUS | 209182-001 | May 4, 2018 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Amneal | NEOSTIGMINE METHYLSULFATE | neostigmine methylsulfate | SOLUTION;INTRAVENOUS | 210051-001 | Jun 15, 2018 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.